Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


New drug shows promise for treating kidney cancer

The new drug axitinib has shown promising activity in patients with cytokine-refractory, metastatic kidney cancer that traditionally have a poor response to drug treatment, according to an Article in the November issue of The Lancet Oncology.

In the USA, kidney cancer is the sixth leading cause of cancer deaths, and is thought to be responsible for nearly 13 000 deaths a year. Kidney cancer is not a single disease, but is made up of several different types of cancer, each of which has different histological features, has a different clinical course, and responds differently to treatment.

The most common type is clear-cell renal cancer, which accounts for 75% of patients. Treatment options are limited and survival is poor, and responses with use of chemotherapy, hormonal, or biological treatment, and even with some of the new targeted drugs, seldom exceed 10%.

Professor Olivier Rixe (University of Paris, France) and colleagues report findings from a phase II trial of axitinib-a selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3-in 52 patients with cytokine-refractory, metastatic kidney cancer (51 of whom had clear-cell renal cancer). 23 patients had complete or partial responses, some of which were long-lasting: 12 of these patients progressed during the study, with a duration of response ranging from around 4 months to 26 months. Additionally, 22 patients showed stable disease for longer than 8 weeks, including 13 patients with stable disease for 24 weeks or longer. Four patients had early disease progression. 30 patients had hypertension related to the treatment, but side-effects in general were manageable and controlled by dose modification or supportive care.

Selectively targeting a single growth factor receptor pathway could provide the potential to rationally adjust dosages and combine drugs directed at specific parts of the pathway to minimise toxicity and achieve the optimum therapeutic benefit. Professor Rixe concludes that “The objective response and time to progression in our study suggest that axitinib might be a promising drug in the treatment of patients with metastatic renal-cell cancer; although a randomised controlled trial is needed to confirm this finding.”

In an accompanying Reflection and Reaction comment, Dr W Marston Linehan (National Cancer Institute, Bethesda, MA, USA) states that these findings “suggest that a drug such as axitinib has promise as a second-line treatment in cytokine-refractory metastatic renal-cell carcinoma, and might have potential as first-line treatment or in combination with other agents targeting the Von Hippel-Lindau pathway (or both).”

Tony Kirby | alfa
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Physicists made crystal lattice from polaritons

20.03.2018 | Physics and Astronomy

Mars' oceans formed early, possibly aided by massive volcanic eruptions

20.03.2018 | Physics and Astronomy

Thawing permafrost produces more methane than expected

20.03.2018 | Earth Sciences

Science & Research
Overview of more VideoLinks >>>